1-9 of 9
Farhad Ravandi-Kashani, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Srdan Verstovsek, MD, PhD, Ayalew Tefferi, M.D., Steven Kornblau, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2007) 110 (11): 3543.
https://doi.org/10.1182/blood.V110.11.3543.3543
Published: 2007
Journal Articles

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

Michael Rytting, MD, Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashani, M.D., Sherry Pierce, R.N., Elihu Estey, M.D.
Journal: Blood
Blood (2007) 110 (11): 1851.
https://doi.org/10.1182/blood.V110.11.1851.1851
Published: 2007
Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.
Journal: Blood
Blood (2006) 108 (11): 2612.
https://doi.org/10.1182/blood.V108.11.2612.2612
Published: 2006
Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.
Journal: Blood
Blood (2006) 108 (11): 2652.
https://doi.org/10.1182/blood.V108.11.2652.2652
Published: 2006
Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.
Journal: Blood
Blood (2006) 108 (11): 3636.
https://doi.org/10.1182/blood.V108.11.3636.3636
Published: 2006
Journal Articles

Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Gautam Borthakur, M.D., Claude Nicaise, M.D., Inga Sams, M.D., Francis Giles, M.D., Ayalew Tefferi, M.D.
Journal: Blood
Blood (2006) 108 (11): 3627.
https://doi.org/10.1182/blood.V108.11.3627.3627
Published: 2006
Journal Articles

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Alfonso Quintas-Cardama, MD, Ayalew Tefferi, M.D., Jorge Cortes, M.D., Animesh Pardanani, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Pat Ault, R.N., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 4902.
https://doi.org/10.1182/blood.V108.11.4902.4902
Published: 2006
Journal Articles

Imatinib Mesylate for Patients (pts) with Hypereosinophilic Syndrome (HES) and Systemic Mastocytosis (SM): A Phase II Trial.

Elias Jabbour, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Dan Jones, Ph.D., M.D., Susan O’Brien, M.D., Raja Luthra, Ph.D., Farhad Ravandi-Kashani, M.D., William Wierda, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Jorge Cortes, M.D.
Journal: Blood
Blood (2004) 104 (11): 4752.
https://doi.org/10.1182/blood.V104.11.4752.4752
Published: 2004
Journal Articles

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

Jorge Cortes, M.D., Susan O’Brien, M.D., Srdan Verstovsek, M.D., George Daley, M.D., Charles Koller, M.D., Alessandra Ferrajoli, M.D., Odeal Pate, R.N., Stefan Faderl, M.D., Farhad Ravandi-Kashani, M.D., Moshe Talpaz, M.D., Yali Zhu, Ph.D., Paul Statkevich, Ph.D., Mary Sugrue, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1009.
https://doi.org/10.1182/blood.V104.11.1009.1009
Published: 2004